Rule 1: If there exists a functional group such as "-COOH" or "-SO3H" in the molecular structure, then it may lead to adverse effects on the blood and lymphatic systems. This rule applies to molecules labeled as 1 for both smiles strings CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 and C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N.
Rule 2: If the molecular structure contains a heterocyclic ring, especially those containing nitrogen atoms like pyridine or pyrimidine, it may also contribute to adverse effects on the blood and lymphatic systems. This rule applies to molecules labeled as 1 for both smiles strings CC1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F and CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3.
Rule 3: If the molecular structure has multiple aromatic rings connected by conjugated double bonds, it may increase its ability to penetrate cell membranes and potentially cause adverse effects on the blood and lymphatic systems. This rule applies to molecules labeled as 1 for smiles

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH2) or a nitro group (-NO2), then it may have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to molecules represented by SMILES strings "CCCNN(CSc1ccc(cc1)I)C(=O)Nc2ccccc2Br", "Oc1ccc(nc2nccs2)no1", "CCON1C(=O)C2(C(=O)NC(=O)C2(C)C)C(=O)N1", "CC(C)NNC(=O)C(C)(C)C(=O)OCC(C)(C)C", "CC(C)CON(C(=O)C(C)(C)C)C(C)(C)C", "CC(C)CNS(=O)(=O)C1=CC=C(C=C1)C(=O)O", "CC(C)CNT(C)(C)C", "CC(C)CN(C)C", "CC(C)CN(SCC)C", "CC(C)CN(C(=O)C(C)(C)C)C(C)(C)C", "CC(C)CN(C(=O)C(C)(C)C)C(C)(C)C", "CC(C)CN(C(=O)C(C)(C)C)C(C)(C)C", "CC(C)CN(C(=O)C(C)(C)C)C(C)(C)C", "CC(C)CN(C(=O)C(C)(C)C)C(C)(C)C", "CC(C)CN(C(=O)C(C)(C)C)

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH2) or a benzene ring with one or more chlorine atoms attached, then it may have the potential to cause adverse effects in the blood and lymphatic systems. The first example in the dataset contains both these features and has been labeled as having side-effect activity.
Rule 2: If the molecule contains a carbonyl group (-C=O) connected to two carbon atoms, which are also bonded to each other through another single bond, then it may have the potential to cause adverse effects in the blood and lymphatic systems. This feature is present in the second example in the dataset, but it has been labeled as not having side-effect activity.
Rule 3: If the molecule contains a nitrogen atom bonded to four different carbon atoms, at least one of which is also bonded to a hydrogen atom, then it may have the potential to cause adverse effects in the blood and lymphatic systems. This feature is present in the third example in the dataset, which has been labeled as having side-effect activity.

================================

Rule 1: If a compound contains a sulfonamide group (-SO2NH-), it may have adverse effects on the blood and lymphatic systems. The first two molecules in the dataset contain this functional group and they both have label 1 indicating their potential for causing such effects.
Rule 2: Compounds containing carboxylic acid groups (-COOH) may also have adverse effects on the blood and lymphatic systems if they are conjugated with amines or amides. The third molecule in the dataset contains a carboxylic acid group but it does not have any amine or amide conjugation, so it has label 0.
Rule 3: If a compound contains a nitro group (-NO2), it may be associated with adverse effects on the blood and lymphatic systems due to its ability to form reactive intermediates under certain conditions. The fifth molecule in the dataset contains a nitro group and it has label 1.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a cyano group (-CN) or a carbonyl group (-C=O), then it may have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to molecules represented by SMILES strings C1=NC2=C(C(=N1)N)N=CN2CCOCP(=O)(O)O, CCC(CO)(P(=O)(O)O)P(=O)(O)O)CN, CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)O)O.C(C(CO)(CO)N)O, C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O, CCC1=C2C=C3C(=C(C(=CC4=NC(=CC5=NC(=CC(=C1C)N2)C(=C5CCC(=O)O)C)C(=C4C)CCC(=O)O)N3)C(C)O)C.[Na+], CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.[Gd+3], CCC(CO)NC(=O)C1CN(C2CC3

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a cyano group (-CN) or a carbonyl group (-C=O), then it may have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to molecules represented by SMILES strings C1=NC2=C(C(=N1)N)N=CN2CCOCP(=O)(O)O, CCC(CO)(P(=O)(O)O)P(=O)(O)O)CN, CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)O)O.C(C(CO)(CO)N)O, C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O, CCC1=C2C=C3C(=C(C(=CC4=NC(=CC5=NC(=CC(=C1C)N2)C(=C5CCC(=O)O)C)C(=C4C)CCC(=O)O)N3)C(C)O)C.[Na+], CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.[Gd+3], CCC(CO)NC(=O)C1CN(C2CC3

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to blood and lymphatic system disorders:
Rule 1: If a molecule contains a carbonyl group (represented by the functional group symbol C=O) followed by a nitrogen atom, then it may have the potential to cause adverse effects in relation to blood and lymphatic system disorders. This rule applies to molecules represented by SMILES strings labeled as "1" in the dataset. For example, the first molecule listed in the dataset, CC(=O)NO, satisfies this condition and is labeled as "1" because it is known to cause adverse effects in humans.
Rule 2: If a molecule contains a cyano group (represented by the functional group symbol CN) attached to a carbon atom adjacent to a double bond, then it may have the potential to cause adverse effects in relation to blood and lymphatic system disorders. This rule also applies to molecules represented by SMILES strings labeled as "1" in the dataset. For example, the second molecule listed in the dataset, CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N, satisfies this condition and is labeled as "1" because it is known to cause adverse effects in humans.
Rule 3: If a molecule contains a sulfonamide group (represented by the functional group symbol SO2NH) connected to a benzene ring through a single bond, then it may have the potential to cause adverse effects in relation to blood and lymphatic system disorders. This rule

================================

Rule 1: If there exists a benzene ring in the molecular structure, then it may have potential side effects on the blood and lymphatic systems. The presence of this functional group indicates that the compound has the ability to bind to receptors or enzymes involved in these biological processes. Therefore, molecules containing such groups should be carefully evaluated for their safety profiles before being used as drugs.
Rule 2: If the molecular structure contains a sulfonamide group, i.e., R-SO2NH2, it may also exhibit toxicity towards the blood and lymphatic systems. Sulfonamides are known to interfere with folic acid metabolism, which can lead to various health problems including anemia, bone marrow suppression, and megaloblastic anemia. Hence, compounds possessing this moiety must be cautiously considered when designing new drug candidates.
Rule 3: If the molecular structure includes a nitro group, i.e., -NO2, it could potentially trigger allergic reactions and other immune responses. Nitro compounds are often associated with skin irritation, respiratory distress, and even cancer. Therefore, caution should be exercised while using substances containing this functional group.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a nitro group (-NO2), then it may have the potential to cause adverse effects in the blood and lymphatic systems. The first two molecules in the dataset contain these groups and they both have labels of 1, indicating their ability to cause such effects.
Rule 2: If the molecule contains a halogen atom (such as chlorine or fluorine) attached to a benzene ring, then it may also have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to the third and fourth molecules in the dataset, which both have labels of 1.
Rule 3: If the molecule contains a carbonyl group (-C=O) connected to a nitrogen atom, then it may also have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to the fifth molecule in the dataset, which has a label of 1.
It's important to note that these rules are based solely on the limited information provided by this small dataset and should be used cautiously until further research can confirm their validity.

================================

Rule 1: If the molecular structure contains a sulfonamide group (-SO2NH-) or a carboxylic acid group (-COOH), then it may have adverse effects on the blood and lymphatic systems. The presence of these functional groups indicates that the compound has the potential to interact with proteins in the body, which could lead to unwanted side effects.
Rule 2: If the molecular structure contains a nitro group (-NO2), then it may be associated with adverse effects on the cardiovascular system. Nitro compounds can irritate the skin and mucous membranes, and some studies suggest they may also increase the risk of heart disease.
Rule 3: If the molecular structure contains a benzene ring, then it may be associated with adverse effects on the immune system. Benzene is known to be carcinogenic, meaning it can cause cancer, and some studies suggest it may also affect the immune system.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a nitro group (-NO2), then it may have the potential to cause adverse effects in the blood and lymphatic systems. The first two molecules in the dataset contain these groups and they both have labels indicating their ability to cause such effects.
Rule 2: If the molecule contains a benzene ring connected to a carbonyl group (-C=O) through a single bond, then it may also have the potential to cause adverse effects in the blood and lymphatic systems. This structure is present in the third molecule in the dataset and its label indicates this possibility.
Rule 3: If the molecule contains a conjugated system consisting of alternating double bonds and single bonds, then it may also have the potential to cause adverse effects in the blood and lymphatic systems. This structure is present in the sixth molecule in the dataset and its label indicates this possibility as well.

================================

Rule 1: If the molecular structure contains a functional group such as CN or NO2, then it has a high probability of causing adverse effects on the blood and lymphatic systems. The presence of these groups may increase the reactivity of the molecule and lead to interactions with biological molecules.
Rule 2: If the molecular structure contains a benzene ring, then it also has a high probability of causing adverse effects on the blood and lymphatic systems. Benzene is known to be carcinogenic and can disrupt normal cell growth and division.
Rule 3: If the molecular structure contains a long carbon chain, then it may have low toxicity but could potentially interfere with lipid metabolism in the body. This could lead to changes in cholesterol levels and other metabolic processes.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH2) or a similar functional group, it may have the potential to cause adverse effects in the blood and lymphatic systems. The presence of this group is known to cause allergic reactions and other types of toxicity.
Rule 2: If the molecule contains a halogen atom such as chlorine (Cl) or fluorine (F), it may also have the potential to cause adverse effects in the blood and lymphatic systems. Halogen atoms are known to increase the reactivity of molecules and can lead to toxic reactions.
Rule 3: If the molecule contains a nitrogen-containing ring structure such as pyridine or pyrimidine, it may also have the potential to cause adverse effects in the blood and lymphatic systems. Nitrogen-containing rings are known to interact with biological molecules and can disrupt normal cellular processes.

================================

Rule 1: The presence of certain functional groups in a molecule may indicate its potential for causing adverse effects on the blood and lymphatic systems. For example, the molecule in SMILES string "CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O" contains a cyclic ether group which has been associated with toxicity. Therefore, this molecule may have the potential to cause adverse effects on the blood and lymphatic systems.
Rule 2: The molecular structure and size may also play a role in determining the potential for adverse effects. For instance, the molecule in SMILES string "C[C@H]([C@@H](C(=O)O)N)O[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO[C@@]2(C[C@@H]([C@H]([C@@H](O2)[C@@H]([C@@H](CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C" contains a carbamoyl group which is known to be toxic when present in high concentrations. Additionally, the molecule is relatively large and complex, which may increase its likelihood of interacting with biological molecules and causing adverse effects.
Rule

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-), it may have side-effects related to blood and lymphatic system disorders. The first molecule in the dataset contains this functional group and has been labeled as having such side-effects.
Rule 2: If the molecule contains a carbonyl group (-C=O) adjacent to a double bond or triple bond, it may also have side-effects related to blood and lymphatic system disorders. This rule applies to the second and third molecules in the dataset.
Rule 3: If the molecule contains a chlorine atom attached to a carbon atom, it may not have any significant side-effects related to blood and lymphatic system disorders. This rule applies to the sixth molecule in the dataset.
It's important to note that these rules are based solely on the limited information provided by the given dataset and should be used with caution. Further research and testing would be needed to confirm their validity and applicability to other molecules.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a sulfonyl group (-SO2-) or a nitro group (-NO2), then it may have the potential to cause adverse effects in the blood and lymphatic systems. The first two molecules in the dataset contain these groups and they both have labels indicating their association with such effects.
Rule 2: If the molecule contains iodine atoms, then it may not have the potential to cause adverse effects in the blood and lymphatic systems. The third molecule in the dataset contains one iodine atom and its label indicates no association with such effects.
Rule 3: If the molecule contains a benzene ring, then it may not have the potential to cause adverse effects in the blood and lymphatic systems. The sixth molecule in the dataset contains a benzene ring but its label indicates no association with such effects.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to blood and lymphatic system disorders:
Rule 1: If the molecule contains a carboxylic acid group (-COOH) or its derivatives such as esters (-COOR) or amides (-CONR2), then it may have the potential to cause adverse effects in relation to blood and lymphatic system disorders. This rule applies to molecules 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63

================================



================================

Rule 1: If there is a presence of functional groups such as sulfonamide or nitro group in a compound, then it may have potential side effects on the blood and lymphatic systems. The given SMILES strings with labels 1 contain these functional groups which indicate their possible association with adverse reactions.
Rule 2: A compound containing aromatic rings may also exhibit similar side effects if they are substituted with certain functional groups like halogens or amines. This rule applies to the second and third SMILES strings where the compounds contain benzene ring attached to various substituents.
Rule 3: Compounds having polar functional groups like carboxylic acid, hydroxyl, or amino groups may interact with biological molecules leading to toxic effects. The last two SMILES strings with labels 1 possess these types of functionalities indicating their probable involvement in causing toxicity.

================================

Rule 1: The presence of functional groups such as carbonyl group (C=O) or carboxyl group (COOH) in a molecule may increase its likelihood of causing adverse effects on the blood and lymphatic systems. This rule can be applied to molecules 1, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.
Rule 2: Molecules containing aromatic rings may also have higher chances of causing adverse effects due to their ability to interact with biological receptors. Therefore, this rule can be applied to molecules 2, 3, 4, 5, 6, 7, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.
Rule 3: The molecular weight of a compound may affect its bioavailability and toxicity. Generally, smaller molecules tend to be more bioavailable and less toxic than larger ones. However, there may be exceptions to this rule depending on other factors such as chemical structure and mode of action. Therefore, this rule cannot be used alone to predict the potential adverse effects of a molecule but should be considered along with other factors. It can be applied to all molecules listed above.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a halogen atom such as chlorine or bromine, then it may have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to molecules 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.
Rule 2: If the molecule contains a nitro group (-NO2), then it may have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to molecules 2 and 3.
Rule 3: If the molecule contains a sulfonyl group (-SO2R), then it may have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to molecules 4 and 5.
It's important to note that these rules are based solely on the provided dataset and may not apply to all cases. It's always best to consult with a qualified chemist before making any conclusions about the safety of a particular compound.

================================

Rule 1: If a compound contains a functional group such as "CC(=O)NSCC1CNN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F" or "C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F", then it has a high probability of causing adverse effects on the blood and lymphatic systems.
Rule 2: If a compound contains a halogen atom like chlorine in its structure, for example "C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl", then it may not have any significant impact on the blood and lymphatic systems.
Rule 3: If a compound contains metal ions such as sodium and iron in its formula, for instance "C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.[Na+].[Fe+3]", then it could potentially lead to adverse reactions in the body due to their toxicity.

================================

Rule 1: The presence of a sulfonamide group (-SO2NH-) in a compound increases its likelihood of causing adverse effects on the blood and lymphatic systems. This rule applies to compounds with SMILES strings starting with "CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl" or "CC1(C(=O)N(C(=O)O1)C)C".
Rule 2: Compounds containing a nitro group (-NO2) may have a higher risk of causing adverse effects on the blood and lymphatic systems. This rule applies to compounds with SMILES strings starting with "CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O" or "C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3".
Rule 3: A compound's ability to form hydrogen bonds with other molecules may increase its potential for causing adverse effects on the blood and lymphatic systems. This rule applies to compounds with SMILES strings starting with "CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C" or

================================

Rule 1: If a compound contains a sulfonamide group (-SO2NH-), it may have adverse effects on the blood and lymphatic systems. The first two molecules in the dataset contain this functional group and they both have label 1 indicating their potential for causing such effects.
Rule 2: Compounds containing carboxylic acid groups (-COOH) may also have adverse effects on the blood and lymphatic systems if they are conjugated with amines or amides. The third molecule in the dataset contains a carboxylic acid group but it does not have any amine or amide conjugation, so it has label 0.
Rule 3: If a compound contains a nitro group (-NO2), it may be associated with adverse effects on the blood and lymphatic systems due to its ability to form reactive intermediates under certain conditions. The fifth molecule in the dataset contains a nitro group and it has label 1.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH2) or a halogen atom such as chlorine (Cl), then it may have the potential to cause adverse effects in the blood and lymphatic systems. The first example in the dataset contains both these groups and is labeled as having side-effect activity.
Rule 2: If the molecule contains a fluorine atom (F) at position 8 of the fluorene ring, then it may not have the potential to cause adverse effects in the blood and lymphatic systems. The second example in the dataset does not contain this functional group and is labeled as not having side-effect activity.
Rule 3: If the molecule contains a zinc ion (Zn), then it may not have the potential to cause adverse effects in the blood and lymphatic systems. The last example in the dataset contains a Zn ion but is labeled as not having side-effect activity.

================================

Rule 1: If a compound contains a functional group such as "CC(=O)NSCC1CNN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F" or "C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F", then it has a high probability of causing adverse effects on the blood and lymphatic systems.
Rule 2: If a compound contains a halogen atom like chlorine in its structure, for example "C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl", then it may not have any significant impact on the blood and lymphatic systems.
Rule 3: If a compound contains metal ions such as sodium and iron in its formula, for instance "C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.[Na+].[Fe+3]", then it could potentially lead to adverse reactions in the body due to their toxicity.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in relation to blood and lymphatic system disorders:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a carboxylic acid group (-COOH), then it may have the potential to cause adverse effects related to blood and lymphatic system disorders. This rule applies to molecules numbered 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects in the blood and lymphatic systems:
Rule 1: If a molecule contains a chlorine atom attached to a carbon atom, then it may have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to molecules labeled as 1 in the dataset.
Rule 2: If a molecule contains a nitrogen atom bonded to four other atoms, including two carbon atoms, one oxygen atom, and one hydrogen atom, then it may have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to molecules labeled as 1 in the dataset.
Rule 3: If a molecule contains a benzene ring structure, then it may have the potential to cause adverse effects in the blood and lymphatic systems. This rule applies to molecules labeled as 1 in the dataset.

================================

Rule 1: The presence of halogen atoms such as bromine or chlorine in the molecular structure may increase the likelihood of causing adverse effects on the blood and lymphatic systems. This rule can be applied to molecules labeled as 1 for their structures containing halogens like Br or Cl. For example, compound number 7 contains two bromine atoms and has been reported to have side-effects on the immune system.
Rule 2: The presence of multiple double bonds between carbon atoms in the molecular structure may also increase the likelihood of causing adverse effects on the blood and lymphatic systems. This rule can be applied to molecules labeled as 1 for their structures containing conjugated double bonds. For instance, compounds numbers 8 and 9 contain multiple double bonds and have been associated with various types of cancer.
Rule 3: The presence of certain functional groups such as sulfonyl groups or nitro groups in the molecular structure may decrease the likelihood of causing adverse effects on the blood and lymphatic systems. This rule can be applied to molecules labeled as 0 for their structures containing these functional groups. For example, compound number 12 does not contain any sulfur or nitrogen atoms but has no known side-effects on the blood and lymphatic systems.

================================

Rule 1: The presence of halogen atoms such as bromine or chlorine in the molecular structure may increase the likelihood of causing adverse effects on the blood and lymphatic systems. This rule can be applied to molecules labeled as 1 for their structures containing halogens like Br or Cl. For example, compound number 7 contains two bromine atoms and has been reported to have side-effects on the immune system.
Rule 2: The presence of multiple double bonds between carbon atoms in the molecular structure may also increase the likelihood of causing adverse effects on the blood and lymphatic systems. This rule can be applied to molecules labeled as 1 for their structures containing conjugated double bonds. For instance, compounds numbers 8 and 9 contain multiple double bonds and have been associated with various types of cancer.
Rule 3: The presence of certain functional groups such as sulfonyl groups or nitro groups in the molecular structure may decrease the likelihood of causing adverse effects on the blood and lymphatic systems. This rule can be applied to molecules labeled as 0 for their structures containing these functional groups. For example, compound number 12 does not contain any sulfur or nitrogen atoms but has no known side-effects on the blood and lymphatic systems.

================================

